WallStSmart

20/20 Biolabs, Inc. Common Stock (AIDX)vsEdwards Lifesciences Corp (EW)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Edwards Lifesciences Corp generates 327059% more annual revenue ($6.67B vs $2.04M). EW leads profitability with a 15.3% profit margin vs -285.0%. EW earns a higher WallStSmart Score of 54/100 (C-).

AIDX

Hold

36

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 5.0Quality: 6.0
Piotroski: 4/9Altman Z: -13.90

EW

Buy

54

out of 100

Grade: C-

Growth: 5.3Profit: 8.0Value: 5.3Quality: 8.5
Piotroski: 3/9Altman Z: 4.48
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for AIDX.

EWUndervalued (+69.2%)

Margin of Safety

+69.2%

Fair Value

$257.48

Current Price

$107.15

$150.33 discount

UndervaluedFair: $257.48Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AIDX3 strengths · Avg: 9.0/10
Revenue GrowthGrowth
36.5%10/10

Revenue surging 36.5% year-over-year

Debt/EquityHealth
0.189/10

Conservative balance sheet, low leverage

Price/BookValuation
1.6x8/10

Reasonable price relative to book value

EW4 strengths · Avg: 9.8/10
Operating MarginProfitability
30.1%10/10

Strong operational efficiency at 30.1%

Debt/EquityHealth
0.0610/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.4810/10

Safe zone — low bankruptcy risk

Market CapQuality
$59.81B9/10

Large-cap with strong market position

Areas to Watch

AIDX4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$2.62M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-354.6%2/10

ROE of -354.6% — below average capital efficiency

Free Cash FlowQuality
$-610,8142/10

Negative free cash flow — burning cash

EW3 concerns · Avg: 3.0/10
PEG RatioValuation
2.144/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

P/E RatioValuation
60.5x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : AIDX

The strongest argument for AIDX centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 36.5% demonstrates continued momentum.

Bull Case : EW

The strongest argument for EW centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 15.3% and operating margin at 30.1%. Revenue growth of 10.5% demonstrates continued momentum.

Bear Case : AIDX

The primary concerns for AIDX are EPS Growth, Market Cap, Return on Equity.

Bear Case : EW

The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 60.5x leaves little room for execution misses.

Key Dynamics to Monitor

AIDX profiles as a hypergrowth stock while EW is a mature play — different risk/reward profiles.

EW carries more volatility with a beta of 0.83 — expect wider price swings.

AIDX is growing revenue faster at 36.5% — sustainability is the question.

EW generates stronger free cash flow (507M), providing more financial flexibility.

Bottom Line

EW scores higher overall (54/100 vs 36/100), backed by strong 15.3% margins and 10.5% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

20/20 Biolabs, Inc. Common Stock

HEALTHCARE · MEDICAL DEVICES · USA

20/20 Biolabs, Inc. (AIDX) is a pioneering biotechnology company dedicated to advancing genomic research and diagnostics through its cutting-edge laboratory services. Focused on improving the accuracy and efficiency of genetic testing for both clinical and research applications, the company is set to establish itself as a leader in the molecular diagnostics market. With a strategic emphasis on personalized medicine and a robust portfolio of state-of-the-art technologies, 20/20 Biolabs is well-positioned to meet the surging demand for genomic data and capitalize on emerging opportunities within the dynamic biotechnology landscape. Its innovative approach and strong market presence reflect a promising growth trajectory in an industry characterized by rapid advancements.

Edwards Lifesciences Corp

HEALTHCARE · MEDICAL DEVICES · USA

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.

Visit Website →

Want to dig deeper into these stocks?